Skip to main content

Research Repository

Advanced Search

Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England

Kuo, Chang-Fu; Grainge, Matthew J.; Mallen, Christian; Zhang, Weiya; Doherty, Michael

Authors

Chang-Fu Kuo

Christian Mallen

Michael Doherty



Abstract

Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription.

Citation

Kuo, C.-F., Grainge, M. J., Mallen, C., Zhang, W., & Doherty, M. (2014). Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. Journal of the American Medical Association, 312(24), https://doi.org/10.1001/jama.2014.14484

Journal Article Type Article
Acceptance Date Aug 12, 2014
Publication Date Dec 24, 2014
Deposit Date Aug 18, 2016
Journal Journal of the American Medical Association
Print ISSN 0098-7484
Electronic ISSN 1538-3598
Publisher American Medical Association
Peer Reviewed Peer Reviewed
Volume 312
Issue 24
DOI https://doi.org/10.1001/jama.2014.14484
Public URL https://nottingham-repository.worktribe.com/output/740521
Publisher URL http://jama.jamanetwork.com/article.aspx?articleid=2084879
Contract Date Aug 18, 2016